SCHEMBL2265490

SCHEMBL2265490

N#CCC(=O)NCCc1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 2/20 0.70
HDAC3 O15379 2/20 0.55
HDAC1 Q13547 2/20 0.55
HDAC2 Q92769 2/20 0.55
HDAC10 Q969S8 2/20 0.55
HDAC11 Q96DB2 2/20 0.55
HDAC8 Q9BY41 2/20 0.55
HDAC6 Q9UBN7 2/20 0.55
NCOR2 Q9Y618 2/20 0.55
HDAC4 P56524 1/20 0.55
HDAC9 Q9UKV0 1/20 0.55
CA12 O43570 2/20 0.54
CA2 P00918 2/20 0.54
CA9 Q16790 2/20 0.54
HPGD P15428 2/20 0.53
ABCB1 P08183 1/20 0.53
ABCG2 Q9UNQ0 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
EPHX1 P07099 1/20 0.53
PLAAT5 Q96KN8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2263117 0.90 L3MBTL1 (0.68) MCL1HPGDL3MBTL1EPHX1GAA
SCHEMBL874265 0.89 TRPV1 (0.65) MCL1HPGDL3MBTL1GAANPC1
SCHEMBL4353945 0.85 KDM4E (0.57) MCL1PLAAT5PLAAT4GAANPC1
SCHEMBL8835177 0.83 LMNA (0.57) CA12CA2CA9HPGDL3MBTL1
SCHEMBL6312788 0.83 HPGD (0.60) CA12CA2CA9HPGDPLAAT5
SCHEMBL22802623 0.83 HDAC3 (0.60) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL654148 0.82 MCL1 (1.00) MCL1HPGDL3MBTL1GAARAB9A
SCHEMBL6316429 0.82 ALDH1A1 (0.66) MCL1HPGDPLAAT5PLAAT4GAA
SCHEMBL11253671 0.81 MCL1 (0.96) MCL1HPGDL3MBTL1GAARAB9A
SCHEMBL7765076 0.80 L3MBTL1 (0.79) HDAC3HDAC1HDAC2HDAC10HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020249821-A1 NOVEL ARGINASE INHIBITORS RIJKSUNIVERSITEIT GRONINGEN (NL) 2020-12-17 WO disclosed
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
WO-2010018438-A2 TETRAZOLE GLYCOSIDES HETERO RESEARCH FOUNDATION (IN) 2010-02-18 WO disclosed
EP-2116585-A1 ULTRAVIOLET ABSORBER COMPOSITION Fujifilm Corporation (JP) 2009-11-11 EP disclosed
US-7598419-B2 Compounds for modulating cell proliferation HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2009-10-06 US disclosed
US-7598419-B2 Compounds for modulating cell proliferation HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2009-10-06 US disclosed
US-7598419-B2 Compounds for modulating cell proliferation HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2009-10-06 US disclosed
US-20070243612-A1 Novel Compounds for Modulating Cell Proliferation HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2007-10-18 US disclosed
US-20070243612-A1 Novel Compounds for Modulating Cell Proliferation HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2007-10-18 US disclosed
US-5846942-A Cholecystokinin antagonists, their preparation and therapeutic use WARNER-LAMBERT COMPANY (US) 1998-12-08 US disclosed
WO-1998045293-A1 PYRIMIDO-ISOQUINOLINE COMPOUNDS WITH ANTICONVULSIVE ACTION SMITHKLINE BEECHAM PLC (GB) 1998-10-15 WO disclosed
US-5593967-A Cholecystokinin antagonists, their preparation and therapeutic use WARNER-LAMBERT COMPANY (US) 1997-01-14 US disclosed
EP-0547178-A4 NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE WARNER LAMBERT CO (US) 1994-07-06 EP disclosed
EP-0547178-A1 NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE WARNER-LAMBERT COMPANY (US) 1993-06-23 EP disclosed
WO-1992004045-A1 NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE WARNER-LAMBERT COMPANY (US) 1992-03-19 WO disclosed
US-4208324-A Disperse diaminopyridine-3-azo dyestuffs CIBA-GEIGY CORPORATION (US) 1980-06-17 US disclosed
US-4066637-A BASIC DIAMINOPYRIDINE-(3)-AZO DYESTUFFS CIBA-GEIGY CORPORATION (US) 1978-01-03 US disclosed
US-3991054-A FOR POLYESTERS BASF AKTIENGESELLSCHAFT (DT) 1976-11-09 US disclosed
US-3985763-A DYESTUFFS BAYER AKTIENGESELLSCHAFT (DT) 1976-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070243612-A1 Novel Compounds for Modulating Cell Proliferation MKI67, CCNA1, PCNA MCL1 7/4885HDAC3 1740/4885HDAC1 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.